CARDIOMAGNYL: EFFICACY AND SAFETY
Issue:
11
Year:
2015
The paper considers the efficiency and safety of using a buffered acetylsalicylic acid (ASA) formulation in therapeutic practice. It shows its advantage over other ASA formulations.
Keywords:
acetylsalicylic acid
Cardiomagnyl
platelets
thromboxane A2
cardiovascular diseases
References:
- Barkagan Z.S., Kotovschikova E.F. Sravnitel'nyj analiz osnovnyh i pobochnyh effektov razlichnyh form atsetilsalitsilovoj kisloty // Klin. farmakol. i ter. – 2004; 13 (3): 1–4.
- Vertkin A.L., Aristarhova O.Ju., Adonina E.V. i dr. Bezopasnost' i farmakoekonomicheskaja effektivnost' primenenija razlichnyh preparatov atsetilsalitsilovoj kisloty u patsientov s IBS. RMZh // Kardiologija. – 2009; 17 (9): 570–5.
- Giljarov M.Ju. Mesto atsetilsalitsilovoj kisloty v terapii aterotromboza i ego oslozhnenij // Farmateka. – 2011; 15: 40–3.
- Zhitnikova L.M. Atsetilsalitsilovaja kislota v profilaktike i lechenii serdechno-sosudistyh zabolevanij: klinicheskie rekomendatsii dlja praktikujuschih vrachej // RMZh. – 2012; 14: 708–13.
- Nasonov E.L., Karateev A.E. Porazhenija zheludka, svjazannye s priemom nesteroidnyh protivovospalitel'nyh preparatov // Klin. meditsina. – 2000; 78 (3): 4–10.
- Fonjakin A.V., Geraskina L.A. Kardionevrologicheskie aspekty antitrombotsitarnoj terapii vo vtorichnoj profilaktike serdechno-sosudistyh zabolevanij // Kardiologija. – 2011; 9: 75–81.
- Potupchik T.V., Veselova O.F., Evert L.S. Geviskon pri gastroezofageal'noj refljuksnoj bolezni // Vrach. – 2015; 5: 26–30.
- Savchenko E.A., Grinshtejn Ju.I., Savchenko A.A. i dr. Zavisit li aspirinorezistentnost' ot formy aspirina i metabolicheskoj aktivnosti trombotsitov u bol'nyh s ishemicheskoj bolezn'ju serdtsa posle aortokoronarnogo shuntirovanija // Sibirskoe med. obozrenie.– 2008; 4: 32–7.
- Sychev D.A. Atsetilsalitsilovaja kislota // Spravochnik poliklinicheskogo vracha. – 2015; 1: 51–3.
- Jakovenko E.P., Krasnolobova L.P., Jakovenko A.V. i dr. Vlijanie preparatov atsetilsalitsilovoj kisloty na morfofunktsional'noe sostojanie slizistoj obolochki zheludka u kardiologicheskih patsientov pozhilogo vozrasta // Serdtse. – 2013; 12 (3): 145–50.
- Brooks P., Day R. Nonsteroidalantiinflammatory drugs – differences and similarities // N. Engl. J. Med. – 1991; 324 (24): 1716–25.
- Chen Z. CAST: randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke // Lancet. – 1997; 349: 1641–9.
- Endo H., Sakaib E., Higurashib T. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy // Dig. Liver Dis. – 2012; 44: 833–8.
- Gasbarrini G., Andreone P., Baraldini M. et al. Antacids in gastric ulcer treatment: evidence of cytoprotection // Scand. J. Gastroenterol. – 1990; 25 (Suppl. 174): 44–7.
- 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. Published online: December 17, 2012.
- Hamm C., Bassand J., Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation // Eur. Heart. J. – 2011. Epub. a head of print.
- Hirata Y., Kataoka H., Shimura T. et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin // Scand. J. Gastroenterol. – 2011; 46: 803–9.
- Mancia G., Fagard R., Narkiewicz K. et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. – 2013; 31 (7): 1281–357.
- Patrono C., Coller B., Dalen J. et al. Platelet-active drugs: the relationship among dose, effectiveness, and side effects // Chest. – 2001; 199: 39–63.
- Sandercock P., Counsell C., Gubitz G. et al. Antiplatelet therapy for acute ischaemic stroke // Cochrane Database Syst. Rev. – 2008; 16: CD000029.
- The International Stroke Trial Collaborative Group The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke // Lancet. – 1997; 349: 1569–81.
- The ISIS-2 Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 // Lancet. – 1988; 2: 349–60.
- Van de Werf F., Bax J., Betriu A. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with persistent ST-segment elevation // Eur. Heart J. – 2008; 29: 2909–45.
- Wallace J., McKnight G. The mucoid cap over superficial gastric damage in the rat.A high-pH microenvironment dissipated by nonsteroidalantiinflammatory drugs and endothelin // Gastroenterology. – 1990; 99 (2): 295–304.
- Wijns W., Olh P., Anchin N. et al. ESC Guidelines on myocardial revascularization // Eur. Heart J. – 2010; 31: 2501–55.